Chitosan Non-Particulate Vaccine Delivery System: A Review

Several preclinical and clinical trials have used chitosan, a material produced from shellfish. Results show it’s well-tolerated, stimulates the immune system, and has positive outcomes across various infections. Notably, chitosan has been found effective as an adjuvant for nasal vaccinations, particularly in clinical trials for a norovirus vaccine. When combined with monophosphoryl lipid, chitosan (ChiSys) elicited strong immune responses and provided protective immunity against norovirus challenges. This article summarizes the significant evidence supporting the development of chitosan-adjuvanted vaccines, including key unpublished data. Chitosan is a naturally occurring polysaccharide that has gained significant attention in the pharmaceutical industry. Its unique properties, such as being non-toxic, biodegradable, and sticky, make it an excellent candidate for delivering vaccines and medications. Chitosan also has antiviral properties, making it a promising component for vaccines. Additionally, its chemical structure can be modified to create new versions with improved properties, enhancing its effectiveness as a vaccine adjuvant. Overall, chitosan’s versatility and benefits make it a valuable tool in the development of vaccines and medications. Chitosan, a natural and versatile material, has been widely researched for delivering medications and vaccines. Its ability to enhance the immune response makes it a valuable component in vaccine development. This review focuses on using chitosan as a vaccine adjuvant, exploring its inherent ability to stimulate the immune system. We’ll also discuss various forms of chitosan-based delivery systems, such as; Thermosensitive hydrogels, Microneedles, Conjugates. Additionally, we’ll examine the benefits of using chitosan as a coating material for vaccine carriers.